The effects of colchicine on lipoprotein(a)- and oxidized phospholipid-associated cardiovascular disease risk
Authors' conclusion
In patients with CCS, colchicine reduces cardiovascular disease risk in those with and without elevated Lp(a) but absolute benefits appeared higher in those with Lp(a) ≥ 125 nmol/L. Patients with higher levels of OxPL-apoB experienced greater benefit of colchicine, suggesting that colchicine may be more effective in subjects with heightened oxidation-driven inflammation.
Study context
- Population
- Patients with chronic coronary syndrome (CCS) in the LoDoCo2 biomarker populationbiomarker population
- Participants
- 1,777 patients
- Comparison
- Colchicine vs placebo, by Lp and OxPL levels
- Primary endpoint
- MI, ischaemic stroke or ischaemia-driven revascularization, by biomarker levels
Methodological detailsbiomarker subpopulation
- Biomarker subpopulation
Primary result
As reported in the abstract
- Consistent risk reduction by colchicine with Lp(a) <125 and ≥125 nmol/L and highest vs lowest OxPL-apo(a) tertile
- Pinteraction = 0.92 and 0.66
- Absolute risk reduction, Lp(a) ≥125 vs <125 nmol/L
- 4.4% vs. 2.4%
- Treatment interaction, highest vs lowest OxPL-apoB tertile
- Pinteraction = 0.04
Further findings
Lp(a), OxPL-apo(a) and OxPL-apoB levels
- Similar between colchicine and placebo
Original publication
The effects of colchicine on lipoprotein(a)- and oxidized phospholipid-associated cardiovascular disease risk. Eur J Prev Cardiol. Published 30 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →